An economic evaluation of sevelamer in patients new to dialysis

References

• National Kidney Federation. Chronic kidney disease. Available from http://www.kidney.org.uk/Medical-Info/ckd-info/index.html#common [Last accessed 24 April 2007]
   Google Scholar
• Ansell D, Feest T, Rao Raman, et al. UK Renal Registry Annual Report. UK Renal Registry, Bristol, UK, 2006
   Google Scholar
• Chen RA, Scott S, Mattern WD, et al. The case for disease management in chronic kidney disease. Dis Manag 2006;9:86–92
   PubMedGoogle Scholar
• Thorp ML, Eastman L, Smith DH, et al. Managing the burden of chronic kidney disease. Dis Manag 2006;9:115–21
   PubMedGoogle Scholar
• Levin A. The need for optimal and coordinated management of CKD. Kidney Int Suppl 2005;99 S7–10
   PubMedGoogle Scholar
• Kidney disease outcomes quality initiative, 2003. Available from http://www.kidney.org/professionals/KDOQI/guidelines.cfm 15 April 2007
   Google Scholar
• The Renal Association clinical practice guidelines, 2007. Available from http://www.renal.org/guidelines/module1.html 2 May 2007
   Google Scholar
• Hruska KA, Mathew S, Davies MR, et al. Connections between vascular calcification and progression of chronic kidney disease: therapeutic alternatives. Kidney Int Suppl 2005;99: S142–51
   PubMedGoogle Scholar
• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208–18
   PubMed Web of Science ®Google Scholar
• Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004;65:1914–26
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone diseases in maintenance hemodialysis patients. Kidney Int 2006;70: 771–80
   Google Scholar
• Shanahan CM. Vascular calcification. Curr Opin Nephrol Hypertens 2005;14:361–7
   PubMed Web of Science ®Google Scholar
• Shroff RC Shanahan CM. The vascular biology of calcification. Semin Dial 2007;20:103–9
   Google Scholar
• Li X, Yang H-Y, Giachelli CM. Role of the sodium-dependent phosphate cotransporter, pit-1, in vascular smooth muscle cell calcification. Circ Res 2006;98:905–12 [Epub ahead of print 9 Mar 2006]
   Google Scholar
• Toussaint ND Kerr PG. Vascular calcification and arterial stiffness in chronic kidney disease: implications and management. Nephrology 2007;12:500–9
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245–52
   Google Scholar
• Chertow GM, Burke SK, Dillon MA et al. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999;14: 2907–14
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Caro J, Wilson DA, et al. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value Health 2005;8:549–61
   PubMed Web of Science ®Google Scholar
• Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438–41
   PubMed Web of Science ®Google Scholar
• Manns B, Klarenbach S, Lee H, et al. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 2007;22:2867–78 [Epub ahead of print 25 Jun 2007]
   Google Scholar
• Rayner HC, Pisoni RL, Bommer J, et al. Mortality and hospitalisation in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004;19:108–120
   PubMed Web of Science ®Google Scholar
• Collins AJ, St Peter WL, Dalleska FW, et al. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Health Policy 2000;54:334–41
   Google Scholar
• Netten A, Curtis L. Unit costs of health and social care 2006. Available from http://www.pssru.ac.uk/ [Last accessed 28 Sept 2006]
   Google Scholar
• Chartered Institute of Public Finance and Accountancy (CIPFA). The health service financial database and comparative tool 2005. Croyden: Institute of Public Finance, 2006
   Google Scholar
• British Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary (BNF) 53. Available from http://www.bnf.org.uk/bnf/ [Last accessed 10 April 2007]
   Google Scholar
• de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy 1998;44:215–32
   Google Scholar
• de Wit GA, Merkus MP, Krediet RT, et al. Health profiles and health preferences of dialysis patients. Nephrol Dial Transplant 2002;17:86–92
   PubMed Web of Science ®Google Scholar
• Sennfalt K, Magnusson M, Carlsson P. Comparison of haemodialysis and peritoneal dialysis – a cost utility analysis. Perit Dial Int 2006;22:39–47
   Google Scholar
• National Institute for Clinical Excellence. Technical guidance for manufacturers and sponsors on making a submission to a technology appraisal. London: National Institute for Clinical Excellence, 2001
   Google Scholar
• Remak E, Hutton J, Jones M, et al. Changes in cost-effectiveness over time. The case of epoetin alfa for renal replacement therapy patients in the UK. Eur J Health Econ 2003;4:115–21
   Google Scholar
• Suki W, Zabaneh R, Cangiano J, et al. The DCOR trial: a prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients. Poster presentation at the American Society of Nephrology Annual Conference, 8–13 November 2005, Pennsylvania Convention Center, Philadelphia, Pennsylvania, USA
   Google Scholar
• UK Renal Registry. Available from http://www.renalreg.com/Front_Frame.htm [Last accessed 14 April 2007]
   Google Scholar
• Pharmacy costs. Available from http://www.mypharmacysecure.co.uk/acatalog/Tums.html [Last accessed 14 April 2007]
   Google Scholar